CLLS logo

CLLS
Cellectis

2,578
Mkt Cap
$281.35M
Volume
12,147.00
52W High
$5.48
52W Low
$1.33
PE Ratio
-5.74
CLLS Fundamentals
Price
$3.89
Prev Close
$3.91
Open
$3.89
50D MA
$3.69
Beta
1.18
Avg. Volume
53,466.83
EPS (Annual)
-$0.6761
P/B
5.14
Rev/Employee
$319,540.26
$396.59
Loading...
Loading...
News
all
press releases
Cellectis (NASDAQ:CLLS) Shares Pass Below 200-Day Moving Average - Time to Sell?
Cellectis (NASDAQ:CLLS) Stock Price Passes Below 200 Day Moving Average - Should You Sell...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Cellectis (NASDAQ:CLLS) Given Market Outperform Rating at Citizens Jmp
Citizens Jmp reiterated a "market outperform" rating and issued a $8.00 price objective on shares of Cellectis in a research note on Tuesday...
MarketBeat·11d ago
News Placeholder
Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Cellectis S.A. (NASDAQ:CLLS - Get Free Report) have been given an average rating of "Moderate Buy" by the five ratings firms that are presently covering the stock, Marketbeat Ratings...
MarketBeat·17d ago
News Placeholder
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.read more...
Benzinga·4mo ago
News Placeholder
Cellectis (NASDAQ:CLLS) Share Price Crosses Above Fifty Day Moving Average - Here's Why
Cellectis (NASDAQ:CLLS) Stock Passes Above Fifty Day Moving Average - Should You Sell...
MarketBeat·5mo ago
News Placeholder
Why Cellectis Stock Is Trading Higher Today
Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion efficiency and supports long-term therapeutic potential.read more...
Benzinga·5mo ago
News Placeholder
Cellectis (NASDAQ:CLLS) Shares Cross Above Fifty Day Moving Average - Should You Sell?
Cellectis (NASDAQ:CLLS) Stock Crosses Above 50 Day Moving Average - Here's Why...
MarketBeat·5mo ago
News Placeholder
Cellectis (NASDAQ:CLLS) Posts Earnings Results, Beats Estimates By $0.11 EPS
Cellectis (NASDAQ:CLLS - Get Free Report) posted its quarterly earnings data on Friday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat·6mo ago
News Placeholder
Cellectis Earnings Preview
read more...
Benzinga·6mo ago
News Placeholder
This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?
Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.
barchart.com·1y ago
<
1
2
...
>

Latest CLLS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.